In addition to its portfolio of multinational clinical trials, ECRIN contributes to various 'infrastructure development' projects. Diverse in scope and country involvement, these projects aim to further develop the European clinical research community and to facilitate multinational trials. In some cases, projects may include clinical trials.
Infrastructure Development Projects
The Beyond 1 Million Genomes (B1MG) consortium will provide coordination and support to the 1+ Million Genomes initiative (1+MG), which is based upon the commitment of 21 European Member States and Norway that have signed the Declaration ‘Towards access to at least 1 million sequenced genomes in the EU by 2022’.
B1MG will go ‘beyond’ the 1M genome target and ‘beyond’ the 21 signatory countries. The project will collaborate with an array of international initiatives and consult a range of stakeholders to support the creation of a pan-European genome-based health data infrastructure, encompassing data quality and exchange standards, access protocols and legal guidance.
Recommendations will be translated to a B1MG maturity level model that provides concrete guidance on the steps required to implement personalised medicine, a healthcare approach that takes into account a person’s genetic make-up, at local, regional and national-scale.
B1MG is funded from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 951724.
- 24-11-2020 - B1MG launches Stakeholder Portal
c4c (conect4children) is a large collaborative European network that aims to facilitate the development of new drugs and other therapies for the entire paediatric population.
It is a pioneering opportunity to build capacity for the implementation of multinational paediatric clinical trials whilst ensuring that the needs of babies, children, young people and their families are met.
c4c is committed to meeting the needs of paediatric patients thanks to a novel collaboration between the academic and the private sectors, which includes 33 academic and 10 industry partners from 20 European countries, and more than 50 third parties and around 500 affiliated partners.
c4c endeavours to provide a sustainable, integrated platform for the efficient and swift delivery of high-quality clinical trials in children and young people across all conditions and phases of the drug development process. It also strives to bring innovative processes to all stages of clinical development by generating a new model of organization and of the clinical development process.
c4c has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777389. The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries & Associations (EFPIA).
- 05-09-2018 - c4c Call for Proposals
This Erasmus+ project aims to tackle the skills gaps and mismatches related to European-level clinical trial professionals through curriculum development and preparation of e-learning material for the career development of biomedical (medical, pharmacy, clinical research master) students.
Coordinated by the University of Pecs, this project involves several ECRIN national networks (as direct beneficiaries):
- HECRIN - Hungarian European Clinical Research Infrastructure Network
- F-CRIN - French Clinical Research Infrastructure Network
- PtCRIN - Portuguese Clinical Research Infrastructure Network
- CZECRIN - Czech Clinical Research Infrastructure Network
- Clinical Research Development Ireland
The Clinical Research Initiative for Global Health (CRIGH) aims to support international collaboration on clinical research for the benefit of patients, healthcare professionals, and health systems. The initiative will seek to optimise clinical research programmes in participating countries, to develop global standards on clinical research, to promote the take-up of innovative methodology and technologies, and to enhance institutional capacity to rapidly and efficiently respond to global health challenges.
Launched in 2016, CRIGH is a follow-up to the Organisation for Economic Co-operation and Development (OECD) Global Science Forum (GSF) initiative, introduced in 2009 to foster international cooperation in non-commercial trials. The GSF made various recommendations to address three main challenges to multi-country collaboration: persisting differences in administrative processes; inadequate regulation for some clinical trials; and uneven national and regional support for education, training and infrastructures for academic clinical trials.
CRIGH is the first global initiative to address the wide range of obstacles to global cooperation in clinical research, facilitating both multi-country commercial and non-commercial trials.
CRIGH includes six projects:
- Infrastructure and funding: developing a network of high-quality and interoperable clinical trial units (CTUs), and promoting additional funding for independent, international trials.
- Global core competencies: promoting harmonized education, training and careers for investigators and clinical research professionals.
- Research ethics: promoting quality, consistency and training among research ethics committees.
- Patient involvement: fostering the involvement of patients as trial participants and in trial design.
- Comparative effectiveness research and socio-economic impact: promoting methodologies for efficient comparison of treatment strategies, and assessing the medical, social and economic impact of evidence.
- Regulatory awareness: developing databases on ethical and regulatory requirements, and recommendations to facilitate international cooperation.
CRIGH will primarily focus on investigator-initiated trials and trials involving small and medium enterprises (SMEs).
The CRIGH consortium is composed of Members and Observers - research institutions or organisations, or consortia of research institutions. ECRIN shares the secretariat with the National Institutes of Health (NIH).
Brain research in Europe is a rapidly evolving field, and increasingly at the forefront of science. The complexity of understanding physiological brain functions and brain diseases brings responsibilities to develop novel tools and approaches to advance our understanding of unknown basic brain functions, as well as opportunities to generate novel therapeutic approaches, thus confronting with a major societal challenge in Europe and worldwide. Considering the costs of brain diseases for the European society, and that these costs will increase considerably in the coming years due to the ageing of the European population, the EU and its Member States have made considerable investments in brain research leading to a significant increase of initiatives in this area. Although these initiatives have generated considerable amounts of knowledge and innovative approaches, the translation into new health interventions is hindered by the complexity of the challenge and by excessive fragmentation of the efforts. Effective and efficient collaboration and cooperation among the various initiatives are often identified as a key success factor to achieve brain research full impact. In particular, there is a constant need for strengthening the information flow and accelerating the exchange of experience on the on-going and future projects as well as maintaining continuous dialogue between all the stakeholder groups and initiatives to allow that objectives are aligned and needs are met.
The European Brain Research Area (EBRA) project will fully respond to these needs by bringing together the various stakeholders and major brain research initiatives, at European level and beyond, and creating the conditions for real and effective cross fertilisation, dialogue, building consensus and exploiting research potential to deliver new health interventions in brain disorders.
EBRA is funded by H2020 under GA no. 825348.
The mission of the European Clinical Research Alliance on Infectious Diseases (ECRAID) Business Plan is to reduce the impact of infectious diseases (IDs) on individual and population health by generating rigorous evidence to improve the diagnosis, prevention and treatment of IDs, and to better respond to ID threats.
ECRAID builds on two other European projects: PREPARE and COMBACTE. The new project is expected to generate complementary, sustainable sources of income, ensuring the long-term continuity of activities.
ECRAID-Plan is funded by the European Commission under grant agreement number 825715.
Rare diseases are a major challenge that requires integrated and collaborative efforts from a wide range of stakeholders. To take rare disease collaborative research in Europe to the next level and support achievement of the IRDiRC 2027 goals, the European Commission has approved the European Joint Programme on Rare Diseases (EJP-RD), an EU-wide and patient-centred initiative to foster rare disease research from bench to bedside and back. The programme, due to launch in January 2019, will receive 55 million EUR over 5 years to establish a comprehensive strategy covering funding, research, data, training, tools and clinical aspects to increase the efficiency of results use, diagnosis, drug discovery, patient care and to empowering all stakeholders.
EJP-RD goals include:
- enabling sustainable and interoperable data re-use and sharing based on FAIR principles (Findable, Accessible, Interoperable, Re-usable);
- structuring the connection with European Reference Networks;
- funding high-quality, transformative research, enhancing uptake of research results for translation into healthcare and effectively transferring innovation for exploitation by SMEs and industry;
- promoting adapted research methodologies for rare disease research;
- providing capacity building to all relevant stakeholders for better research in the future;
- ensuring patient involvement in all steps of the research pathway.
This work will be organised into four pillars: I) Collaborative research funding; II) Innovative coordinated access to data and services; III) Capacity building and empowerment; IV) Accelerating translation of high potential projects and improving outcomes of clinical trials in small populations.
Download a poster presenting ECRIN's role in the project (presented at the 7th RD Summer School, 2019)
This initiative has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 825575.
- 14-09-2020 - EJP RD General Assembly Meeting
- 13-01-2020 - EJP RD - RDR Challenges Networking Event
- 07-01-2020 - EJP-RD Networking Support Scheme Now Open
- 06-12-2019 - Postponed! RE(ACT) Congress & IRDiRC Conference 2020
- 20-11-2019 - EJP RD Joint Transnational Call 2020
- 20-11-2019 - Clinical Trials Methodology Demonstration Projects - EJP RD Internal Call for Proposals 2019
- 10-10-2019 - Partner Event: EJP-RD 'Info Day and Brokerage Event' in Istanbul
- 01-10-2019 - European Joint Programme on Rare Diseases (EJP-RD) Support Office Now Online
- 27-11-2018 - Webinar (in French): European Joint Programme on Rare Diseases, the Instrument and Future Calls
EOSC-hub brings together multiple service providers to create the Hub: a single contact point for European researchers and innovators to discover, access, use and reuse a broad spectrum of resources for advanced data-driven research.
For researchers, this will mean broader access to services supporting their scientific discovery and collaboration across disciplinary and geographical boundaries.
The project mobilises providers from the EGI Federation, EUDAT CDI, INDIGO-DataCloud and other major European research infrastructures to deliver a common catalogue of research data, services and software for research.
EOSC-hub collaborates closely with eInfraCentral, EOSCpilot, GÉANT 4.2, OpenAIRE-Advance and the RDA Europe 4.0 projects to deliver a consistent service offer for research communities across Europe.
EOSC-hub is funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement 777536. The generous EU funding received by the project is complemented with a contribution from the EGI Foundation and its participants, and in-kind contributions made available by service providers of the EGI Federation.
ECRIN is involved in formulating policies to facilitate the sharing and safe processing of both open and “restricted” data from across European research infrastructures, and promoting current models of good practice on the management of restricted data from around the EOSC-hub consortium.
- 14-09-2020 - EOSC Hub Webinar Series
EOSC-Life brings together the 13 Biological and Medical ESFRI research infrastructures (BMS RIs) to create an open collaborative space for digital biology. By publishing data and tools in a Europe-wide cloud EOSC-Life aims to bring the capabilities of big science projects to the wider research community. Federated user access (AAI) will allow transnational resource access and authorisation. EOSC-Life establishes a novel access model for the BMS RI: through EOSC scientists would gain direct access to FAIR data and tools in a cloud environment available throughout the European Research Area.
EOSC-Life has received funding from the European Union's Horizon 2020 programme under grant agreement number 824087.
- 03-11-2020 - Continued dedication to open access resources for COVID-19 research
- 29-10-2020 - EOSC-Life Open Call for projects sharing data, tools and workflows in the cloud
- 31-10-2019 - EOSC-Life Workshop on Pseudo-Anonymisation of Health Data
- 06-09-2019 - EOSC-Life 'FAIR Enough' Meeting in Brussels
- 04-03-2019 - Press Release: The EOSC-Life project develops an open collaborative space for digital biology in Europe
The EOSCpilot project will support the first phase in the development of the European Open Science Cloud (EOSC) as described in the EC Communication on European Cloud Initiatives . In particular, it will:
- Establish the governance framework for the EOSC and contribute to the development of European open science policy and best practice;
- Develop a number of pilots that integrate services and infrastructures to demonstrate interoperability in various scientific domains;
- Engage with a broad range of stakeholders, crossing borders and communities, to build the trust and skills required for adoption of an open approach to scientific research.
The EOSCpilot project will address some of the key reasons why European research is not yet fully tapping into the potential of data. In particular, it will:
- Reduce fragmentation between data infrastructures by working across scientific and economic domains, countries and governance models;
- Improve interoperability between data infrastructures by demonstrating how data and resources can be shared.
In this way, the EOSC pilot project will improve the ability to reuse data resources and provide an important step towards building a dependable open-data research environment where data from publicly funded research is always open and there are clear incentives and rewards for the sharing of data and resources.
ECRIN is involved in the work package on policy, and in particular is the lead, along with BBMRI, on the sub-task on drivers and constraints for ethics. This subtask will investigate ethical issues related to the use/re-use of data and services and will produce practical recommendations on each of them.
The EOSCpilot has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 739563.
This project involves all existing organisations with the status of a European Research Infrastructure Consortium (ERIC) and consortia.
The aims of the project are to:
- Strengthen coordination and networking, reinforcing the informal ERIC network or its successor framework;
- Support the organisation of specific meetings, targeted thematic workshops focussing on shared challenges such as the development of internal procurement rules, harmonised reporting, VAT exemption practices, insurances and pensions policies and training of governance bodies representatives;
- Support ERICs in preparation, based on best practices;
- Support common communication and outreach activities, and strengthen external representation of ERICs as a stakeholder in consultations and other policy actions that could affect them.
The ERIC Forum project has received funding from the European Union’s Horizon 2020 programme under grant agreement number 823798.
- 24-09-2020 - ERIC-Forum Policy Brief: Funding models for access to ERIC multinational/transnational services
- 14-09-2020 - 1st ERIC Forum Policy Seminar
- 11-02-2020 - ERIC Forum Meeting in Brussels Addresses Progress Made and Activities for the Future
- 06-02-2020 - Press Release: The ERIC Forum Announces New Chair and Vice Chair
- 01-02-2019 - ERIC Forum Kick-Off Meeting
EU-PEARL aims to transform the current approach of conducting single-compound clinical trials into the use
of cross-company Integrated Research Platforms (IRPs), taking into consideration both patients’ interests and the
opportunities from novel molecules for addressing medical needs. Patient-centric data and knowledge sharing have the potential to accelerate the development of new treatments and reduce the operational costs of clinical trials.
EU-PEARL will improve clinical effectiveness, patients’ satisfaction and societal access to timely and affordable medicines and it will shape the clinical trials of the future. This will change the industry paradigm from competition to cooperation in four disease areas and provide the framework for designing IRPs in other disease areas.
The main objectives of EU-PEARL are:
- To create a reusable, accessible and sustainable modular IRP for the design and execution of patient-centric, cross company IRP in any disease area with unmet needs;
- To set up the open, dynamic, patient inclusive IRP governance structure that will manage the appropriate regulatory, ethical, legal, statistical and data utilisation requirements of the IRP;
- To disseminate and exploit the EU-PEARL paradigm through the provision of the necessary common tools, procedures, expertise and operational skills working to the highest scientific, regulatory and ethical standards and best practices, developed jointly by public and industry partners in a consensus-based approach; and
- To create trial-ready IRP networks in the four disease areas of Major Depressive Disorder (MDD), Tuberculosis (TB), Non-Alcoholic Steatohepatitis (NASH) and Neurofibromatosis (NF).
The project kick-off was held from 21-22 November 2019; the scheduled duration of the project is 42 months.
EU-PEARL is funded by Horizon 2020 and the Innovative Medicines Initiative (IMI) under grant agreement number 853966-2.
- 29-09-2020 - CONSORT develops a checklist and guidelines for reporting in randomized platform trials (adaptive design)
- 18-12-2019 - Press Release: The EU-PEARL project aims to shape future drug development through a systematic approach that enables patient focused, cross company collaborative platform trials
- 21-11-2019 - EU Patient- cEntric clinicAl tRial pLatform Kick-Off MEeting
EU-RESPONSE, a 5-year multi-national project, funded by the European Union’s Horizon 2020 research and innovation programme in order to design and run a new adaptive European platform trial on COVID-19 and emerging infectious diseases.
EU-RESPONSE will allow the European expansion of the DisCoVeRy study, a phase III, open-label, adaptive, randomized, controlled, multi-centre clinical trial designed to evaluate the safety and efficacy of medicinal products in hospitalized adult patients diagnosed with COVID-19. The DisCoVeRy trial was originally initiated in France as WHO Solidarity trial “add-on” study and thanks to EU-RESPONSE it will further expand to many other European countries.
Additionally, EU-RESPONSE will allow the building of a new multinational European Adaptive Platform Trial, based on existing initiatives, experiences and competencies – the EU-SolidAct. This will be a flexible platform, providing a modular trial network enabling most, if not all, European hospitals to participate at their preferred level of commitment. EU-SolidAct will aim to run repurposing trials, evaluating combination strategies as well as evaluating efficacy and safety of new compounds entering clinical development on COVID 19. Although in the short-term this project will focus on COVID-19, the mid-term/long-term objectives are to build a platform trial network on emerging infectious diseases in general. The project also includes a coordination module with the EU-funded RECOVER project, led by ECRIN, ensuring complementarity and cooperation across all large European COVID-19 Adaptive Platform trials, and their capacity to answer the needs of society through dialogue with the EMA, national competent authorities, HTAs and industry partners.
This project aims to:
- Map existing programmes, capacities and expertise and gaps in CELAC countries;
- Facilitate the incorporation of CELAC countries in the International Consortium on Personalized Medicine (ICPerMed) and in the ERA-Net ERAPerMed;
- Foster the participation of CELAC countries in research mobility and transnational projects on PerMed, and create a platform for EU‐CELAC collaboration on PerMed-focused clinical trials
- Promote cross-border learning from Research & Innovation (R&I) and ELSA for implementing innovations between research capacities based in the EU and CELAC countries.
EULAC PerMed has received funding from the European Union’s Horizon 2020 programme under grant agreement number 825173.
- 22-10-2020 - Register for the Personlised Medicine ELSA Workshop
- 14-09-2020 - EULAC-PerMed 3rd Annual Summer School
- 14-09-2020 - EULAC-Permed: 2nd Technical workshop
- 13-05-2020 - EULAC PerMed Newsletter
- 20-12-2019 - The "Big Week” of Personalised Medicine at Montevideo: An EULAC PerMed Event Series
- 20-09-2019 - EULAC-PerMed August 2019 Newsletter (Issue 1)
- 24-07-2019 - EULAC PerMed Upcoming Events
- 10-07-2019 - EULAC PerMed Summer School on Personalised Medicine Research in Health Systems
- 12-06-2019 - EULAC PerMed Website Now Online
The EuroStemCell project, funded by the European Commission’s Horizon 2020 funding programme, aims to help European citizens understand stem cells. Over 400 stem cell labs participate in the project, and contributors include scientists, clinicians, ethicists, social scientists and science communicators. To communicate stem cell research, EuroStemCell has created a website and multilingual content such as non-technical fact sheets on key questions and concepts, and a toolkit of films, comics, lesson plans and games to facilitate education and outreach.
ECRIN is a partner in EuroStemCell, and is currently involved in EuroStemCell’s work on resources for decision-making and interfacing with the press and broadcast media.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 652796.
MiRoR is an innovative and ambitious joint doctoral training programme funded by Marie Skłodowska-Curie Actions, dedicated to Methods in Research on Research in the field of clinical research. ECRIN is involved in the project as a consortium member.
“Research on Research” is an emerging new scientific discipline that aims to reduce waste in research and increase research value. Tens of billions of Euros are wasted each year on studies that are redundant, flawed in their design, never published or poorly reported. The public is the main victim of this waste and reducing waste and increasing value of research represents a major societal challenge.
MiRoR will train 15 PhD students to become the future generation of high-level scientists to develop innovative methods of Research on Research. The students will be awarded with a double degree.
This project is funded by the European Union’s Horizon 2020 Marie Sklodowska Curie Innovative Training Networks- European Joint doctorate (ITN-EJD) under grant agreement number 676207.
- 07-10-2018 - MiRoR Project: 4th Training Event
- 20-06-2017 - Interview with Jacques Demotes on the MiRoR Website
Funded by Horizon 2020, the Paediatric Clinical Research Infrastructure Network (PedCRIN) brings together ECRIN and the European Paediatric Clinical Trial Research Infrastructure (EPCTRI) to develop capacity for multinational paediatric clinical trials.
Launched on January 1st, 2017, the project will last four years and includes five work packages (WPs):
- WP1: Project coordination and implementation of management decisions
- WP2: Definition of the PedCRIN business strategy and governance structure
- WP3: Development of tools specific for paediatric and neonatal trials (trial methodology and outcome measures, adverse event reporting bio-sample management, ethical and regulatory database, monitoring, quality and certification)
- WP4: Provision of operational support to select pilot trials, which will be coordinated by ECRIN with the support of national paediatric coordinators hosted by paediatric networks (that currently exist or are being set-up)
- WP5: Communication targeting user communities (including industry partners) and policymakers, and aiming to empower patients and parents
To learn more about PedCRIN and the need for multinational paediatric clinical studies, see the fact sheet
This project has received funding from the European Union’s Horizon 2020 programme under grant agreement number 731046.
The PERsonalised MedicIne Trials (‘PERMIT’) project on methodological standards for personalised medicine research will establish recommendations ensuring the robustness of personalised medicine trials.
In a series of workshops, participants, partners and selected experts will address the various aspects of methodology, design, data management, analysis and interpretation in personalised medicine research programmes, with the objective of reaching consensus and publishing recommendations.
In particular, the project will undertake a mapping of the literature on methodological practices in the various steps of personalised medicine programmes, and identify needs in terms of standardised methodology. It will also address the design of stratification and validation cohorts, and examine the use of stratification algorithms and robustness of stratification methods. It will also provide recommendations on innovative trial designs for personalised medicine, and will assess personalised vs. non-personalised medicine approaches in clinical trials.
Consortium and partners
The PERMIT consortium is composed of the following participants: pan-European research infrastructures (ECRIN, EATRIS, ELIXIR-LU/UNILU), funders (DLR), HTAs (KCE, ISCIII), patients (EPF), regulatory (ISS), data protection (TMF) and scientific experts.
Partners represent stakeholders interested in the quality of evidence generated by personalised medicine research (industry, medicine agencies, ethics committees, funders, journal editors, HTAs, BBMRI).
PERMIT has received funding from Horizon 2020 under grant agreement number 874825.
- 12-10-2020 - PERMIT project abstract selected for Cochrane special edition
- 07-05-2020 - PERMIT project: Main research methodologies for personalised medicine research
- 30-12-2019 - PERMIT (PERsonalised MedicIne Trials) Kick-Off Meeting
- 30-09-2019 - ICPerMed Vison Paper published: How can personalised approaches pave the way to next-generation medicine?
- 26-08-2019 - PERMIT Project on Methodological Standards for Personalised Medicine Now Funded
RECoVER is a comprehensive research response that addresses the urgent questions for clinical and public health interventions in light of the SARS-CoV-2 outbreak. It does so using a multidisciplinary approach combining clinical studies in primary care and hospitals, epidemiological studies and modelling as well as clinical biological studies, and social sciences.
RECoVER includes the funding of REMAP-COVID, an international Adaptive Platform Trial for COVID-19 therapeutics, which is an extension of the pre-existing REMAP-CAP platform trial for patients hospitalised with community-acquired pneumonia. ECRIN will lead the coordination module between this and the other large COVID-19 European Adaptive Platform trial (EU-RESPONSE) in order to maximize synergies, avoid redundancies, and enable a more efficient search for treatments.
RECoVER is funded by the European Commission under grant agreement number 101003589.
RI-VIS will increase the visibility of European research infrastructures (RIs) to broader scientific communities, industry and strategic partners in third countries.
The RI-VIS consortium has main membership from the life sciences RIs where there is urgent need to improve outreach and strategic partnerships. Partner RIs in other thematic groups ensure that outcomes are relevant to all.
RI-VIS will target communities and stakeholders with current and precise information and match them with RIs to facilitate i) the development of new collaborations, ii) user accessibility, iii) collaborative and innovative actions, iv) funding opportunities, v) knowledge transfer and vi) training opportunities.
RI-VIS will make it easier for new entrants to find out how RIs are organised and funded, where and how to access RI services and where data is available. The communication framework will include several digital platforms to achieve broad reach and generate a communication toolkit to help others benefit from the experiences gained.
RI-VIS has received from the European Union’s Horizon 2020 programme under grant agreement number 824063.
- 22-11-2019 - RI-VIS Africa-Europe Symposium
RISCAPE will provide a comprehensive, peer-reviewed international landscape analysis report on the position and complementarities of the major European research infrastructures (RIs). To achieve this, RISCAPE will establish close links with a stakeholder panel representing the main user groups of the report and will collaborate closely with RI projects and initiatives. The report is intended to inform the EU strategic RI development and policy. This project is in line with the European Commission’s strategy on EU international cooperation in research and innovation.
ECRIN is leading work on biomedical sciences and will draft the landscape analysis report in the biomedical sector.
RISCAPE has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 730974.
- 31-10-2019 - RISCAPE International Landscape Report Launch Event
- 03-02-2017 - RISCAPE Project Launched
RItrain aims to develop a flagship training programme enabling research infrastructures (RIs) across all domains to gain expertise on governance, organisation, financial and staff management, funding, intellectual property (IP), service provision and outreach in an international context. ECRIN is involved in work packages on project management; definition of competencies required by RIs; and continuing professional development for managers of RIs.
RItrain is organising three pilot staff exchanges as part of its mission to share management expertise among European Research Infrastructures. Learn more here
RItrain has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 654156.
- 17-10-2019 - Save the Date: Live Streaming of RItrain Workshop 20-21 Nov. on Building Leadership in European RIs
- 17-10-2019 - Deadline Extended: Call for Applications – EMMRI Third Edition (31 Oct. 2019)
- 22-03-2019 - RItrain Workshop: Building Leadership in European Research Infrastructures
- 26-11-2018 - RItrain Staff Exchange at ECRIN
- 05-11-2018 - Video on Executive Master in Management of Research Infrastructures (EMMRI)
- 24-08-2018 - RItrain Equality, Diversity and Inclusion workshop - 29th & 30th October 2018, UK
- 19-06-2018 - EMMRI: Take the opportunity to improve your managerial skills
- 09-03-2017 - RItrain Executive Masters in Management of Research Infrastructures
- 27-02-2017 - RItrain Staff Exchange
The “SYNergies for Cohorts in Health: integrating the Role of all Stakeholders” (SYNCHROS) project aims to establish a sustainable European strategy for the development of the next generation of integrated population, patient and clinical trial cohorts, thereby contributing to an international strategic agenda for enhanced coordination of cohorts globally.
The project will address the practical, ethical / legal, and methodological challenges to: optimising the exploitation of current and future cohort data in view of developing stratified and personalised medicine as well as facilitating health policy. In particular, SYNCHROS will:
- map the cohort landscape in Europe and large international initiatives;
- identify the best methods for integrating cohort data;
- identify solutions for addressing practical, ethical and legal challenges in integrating data across patient, clinical trial and population cohorts;
- evaluate the use of emerging and new data collection technologies and types of data.
SYNCHROS has received funding from the European Union Horizon 2020 programme under grant agreement number 825884.
- 18-01-2019 - SYNCHROS Kick-Off Meeting
The TBMED (A testing bed for the development of high-risk medical devices) project will establish an open innovation testing bed specialised in the development of high-risk devices (≥Class IIb).
TBMED will provide an integral service to accelerate the development of medical devices reducing time to market, covering technology development from TRL4-7 based on Quality-by-Design (QbD) concept and business management services. QbD concept enhances product and process understanding together with process control, based on robust scientific knowledge and quality risk management. Four different medical devices will be used as case studies.
TBMED has received funding from the European Union Horizon 2020 programme under grant agreement number 825884.
- 15-09-2020 - Open call for MedTech SMEs looking at solutions for COVID19
- 29-11-2019 - Subscription Now Possible to TBMed (A testing bed for the development of high-risk medical devices) Newsletter
- 20-02-2019 - Press Release: An Open-Innovation Test Bed for Medical Devices: Kick-off for new EU Research Project TBMED
TESA II (Trials of Excellence in Southern Africa II) is funded by the European & Developing Countries Clinical Trials Partnership (EDCTP) under GA no.1051-TESAII EDCTP-RegNet-2015.
TESAII was launched in Maputo, Mozambique from 30–31 October 2017. EDCTP is investing almost €3 million in the Mozambique-based consortium, which is coordinated by Dr Eusebio Macete of Manhiça Foundation-Manhiça Health Research Centre (FM-CISM).
The TESA network was established during the first programme of EDCTP with the objective of creating a framework for collaboration, capacity building and training among 9 institutions from 6 different Southern African countries.
In the present project, 13 institutions from 8 different Southern African and 3 European countries came together to strengthen and enhance the capacities for clinical research in Southern Africa built during TESA 1, as well as to increase the collaboration and North-South and South-South networking activities among member institutions.
Besides training programmes designed to ensure career development and retaining research talent and knowledge, African hosting institutions for senior researchers, must have the capacity, the resources and the financial viability to ensure the return of investment in research personnel. Clinical trials and other research studies being conducted at experienced sites will serve as a backbone/platform for training activities. A model of 'on-the-job' training will be implemented. Along these lines, different clinical trials have been identified within the network to be offered as a training opportunity for TESA researchers.
The new project, TRANSVAC-DS (Design study for a European vaccine infrastructure), further builds on the outstanding success and lessons learned of the TRANSVAC1 and TRANSVAC2 projects (www.transvac.org) also funded by the EC and proposes the establishment of a truly sustainable European vaccine infrastructure. The TRANSVAC-DS consortium comprises twenty-five partners from eleven European countries (DE, FR, NL, NO, BE, PT, ES UK, IT, CH and DK) and includes leading academic and research organisations, other research infrastructures and vaccine alliances working in areas related to vaccine development.
While TRANSVAC1/2 have made and are making very significant contributions to supporting the development of innovative vaccines through the provision of state-of-the-art scientific-technical services, TRANSVAC-DS will support the conceptual and technical design of a European vaccine infrastructure.
Specifically, TRANSVAC-DS will describe in detail the maturity of the concept and deliver a five-year business plan that will guide the further establishment of a sustainable European vaccine infrastructure of direct relevance to and benefit for Europe and further afield. It is hoped that at the end of the two-year project a European vaccine infrastructure can rapidly move into the implementation and operation phases and can efficiently support the development of further innovative vaccines for global health.
TRANSVAC DS is funded from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 951668.
TRANSVAC2 is the follow-up project to its successful predecessor project TRANSVAC, the European Network of Vaccine Research and Development funded funded by European Union Framework Programme 7, FP7.
The TRANSVAC2 consortium includes leading European institutions that propose to further advance with the previous initiative towards the establishment of a fully operational and sustainable European vaccine R&D infrastructure.
TRANSVAC2 will support innovation for both prophylactic and therapeutic vaccine development based on a disease-overarching and one-health approach, thereby optimising the knowledge and expertise gained during the development of both human and animal vaccines. This will be achieved by bridging the translational gap in biomedical research, and by supporting cooperation between public vaccine R&D institutions of excellence, related initiatives and networks in Europe, and industrial partners.
TRANSVAC2 will contribute to the development of effective products to address European and global health challenges, to controlling the burden and spread of infectious diseases, and to the reinforcement of the economic assets represented by vaccine developers in Europe.
ECRIN is leading the work package on clinical trial support. In this role, ECRIN will provide information/advice on the development of multinational vaccine clinical trials; provide consulting on appropriate design/methodology for such trials; and support regulatory and ethical submissions in trial participating countries. ECRIN is also involved in the work package on regulatory support.
TRANSVAC2 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 730964.
- 02-04-2020 - TRANVAC2 Open call for Transnational access services
- 25-10-2019 - New TRANSVAC2 Calls: Training and Vaccine Development Services
- 09-05-2019 - TRANSVAC: Deadline Extension for 4th Call for Training Modules
- 01-02-2019 - TRANSVAC workshop on “In vivo imaging of host response to vaccines and infections"
- 15-01-2019 - 3rd Call for TRANSVAC Training Module in Vaccinology
- 05-11-2018 - TRANSVAC: European Vaccine Research and Development Infrastructure
- 31-07-2018 - TRANSVAC Open Call for Vaccine Development Services
The Horizon 2020-funded CORBEL project aims to establish shared services between the European Strategy Forum on Research Infrastructures Biological and Medical Sciences Research Infrastructures (ESFRI BMS RIs)–which includes ECRIN–for the biomedical research community. CORBEL will achieve this by creating cross-infrastructure scientific workflows. A suite of common services will be developed and dynamically updated in response to specific user and research infrastructure needs. Partnerships with user communities working in European programmes such as Joint Programming Initiatives (JPI) or ERA-NETs (European Research Area Networks) and private-public partnerships such as the Innovative Medicine Initiative (IMI) will be facilitated by single access points and joint services.
The illustration below shows how ECRIN interacts specifically in CORBEL with other biomedical RIs, highlighting RI focus areas and disease priorities.
Medical Infrastructure / Users Forum (MIUF)
ECRIN is leading the work package in charge of the creation of a medical infrastructure / users forum (MIUF), which is a body of scientific experts. The MIUF aims to be a key instrument for the efficient development and use of biomedical research in Europe. It will guide the development of shared services and support their incorporation within participating research infrastructures and partner institutions, laying a solid foundation for long-term cooperation.
As part of the MIUF's work, a questionnaire was created to collect the needs and expectations of medical research communities and overall users of RIs. The responses have been collected and analysed in a report. They will be used as input to gather recommendations for continuous improvement and development of new, transversal services.
CORBEL has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 654248.
- 24-06-2020 - ECRIN in European Life Science Research Infrastructures (video)
- 13-01-2020 - New Paper: Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes
- 22-11-2019 - CORBEL Final Open Meeting
- 22-11-2019 - Webinar: How to make your event successful and eligible for EU funding: Event management for Research Infrastructures
- 31-10-2019 - CORBEL Medical Infrastructure Users Forum (MIUF) Meeting (cancelled)
- 31-10-2019 - 2nd CORBEL Service Operator and User Meeting
- 22-11-2018 - Partner News: CORBEL webinar "BBMRI-ERIC Quality Management Services for basic and applied research on human specimens"
- 18-10-2018 - CORBEL: Annual General Meeting
- 16-10-2018 - CORBEL: MIUF Meeting
- 21-09-2018 - CORBEL 3rd Annual General Meeting
- 24-08-2018 - CORBEL Medical Infrastructure Users Forum
- 23-05-2018 - CORBEL launches 2nd Open Call for research projects
- 03-04-2018 - CORBEL 2nd Open Call
- 13-03-2017 - CORBEL 'Medical Infrastructure / Users Forum' (MIUF) Survey Report
- 24-02-2017 - CORBEL Innovation Meeting
- 02-02-2017 - 3rd CORBEL/MIUF Meeting
- 02-02-2017 - CORBEL Final Meeting on Patient-Level Data Sharing
- 24-10-2016 - CORBEL Launches 1st Open Call for Research Projects
- 28-07-2016 - CORBEL Meeting on Survey Outcomes
- 28-07-2016 - CORBEL Meeting on Patient-Level Data-Sharing
- 02-06-2016 - CORBEL Survey on User Needs
- 29-02-2016 - CORBEL Workshop on Access to Individual Patient Data
ECRIN Integrating Activity (ECRIN-IA) is a collaborative project, initially running from 2012 to the end of 2015, funded by the European Commission Framework Program 7 and involving 23 countries (click here for country contacts). Work package (WP) 7 was extended until 2017.
ECRIN-IA’s purpose is to build a consistent organisation for clinical research in Europe, providing generic tools and services to multinational studies, and supporting the construction of pan-European disease-oriented networks that will become ECRIN users and provide clinical research projects. This organisation will improve Europe’s attractiveness to industry, boost its scientific competitiveness, and result in better healthcare for European citizens. Activities are divided into nine work packages (WPs):
- WP1–Management, governance and coordination of the project
Overall management of the project is coordinated by the ECRIN Paris office.
- WP2–Expansion, capacity building and funding
Networking activities promote pan-European expansion, capacity building and partnership with other world regions, and promote appropriate funding mechanisms.
- WP3–Education, e-services and communication
E-services for researchers and education material to train professionals and patients associations are developed in this work package, which also addresses communication with users, patients, citizens and policymakers.
- WP4, 5 & 6–structuring rare disease, medical device and nutrition networks
Structuring European hubs and networks for clinical research on rare diseases (WP4), medical devices (WP5) and nutrition (WP6). The networks will design and conduct multinational clinical studies.
- WP7–Transnational access
Transnational access activities support the cost of multinational extension of clinical trials selected by the ECRIN Scientific Board. Five trials are supported in three areas: MENAC (nutrition); ESCALE and POEM vs LHM (medical devices), RESCUE ESES and IMPACTT (rare diseases).
Identification, assessment and validation of tools for the implementation of risk-based monitoring strategies will improve the efficiency of ECRIN services.
- WP9–Data management
Adaptation of the VISTA Trials data management software will provide a state-of-the-art and efficient Clinical Data Management Tool for multinational clinical trials to the ECRIN user community and for non-commercial clinical research.
This project has received funding from the European Union’s Seventh Framework Programme for Capacities - Research Infrastructures under grant agreement no. 284395.
European Paediatric Translational Research Infrastructure (EPTRI) is a project that arises from the need to find answers to the serious lack of medicines for children in EU and worldwide. It aims to propose developmental models for a future research infrastructure focused on paediatric medicines, integrating technology-driven aspects with clinical trials.
The project ID-EPTRI, coordinated by Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) and funded within the H2020-INFRADEV-01-2017 programme, aims to design the framework for the new RI providing a conceptual design report (CDR) of EPTRI describing the scientific and technical requirements as well as the key components of the new RI. Five technical and scientific domains have been identified:
- Paediatric Medicines Discovery
- Paediatric Pharmacology
- Formulation Science
- Underpinning Paediatric Studies
To harness efficiency in delivery of paediatric research activities and services, EPTRI plans to act as a “paediatric common service” with three already established Research Infrastructures (BBMRI, EATRIS, ECRIN).
EPTRI has received funding from the European Union’s Horizon 2020-INFRADEV-01-2017 programme under grant agreement number 654248.
This H2020 project aimed to: create a European-wide network of procurers; define a common innovation procurement roadmap in the short and long term; and define the public procurement of innovation procedure(s) that best meet needs and support the early detection and screening of functional low vision conditions, or would support the provision for low vision services.
ECRIN was involved in work packages on information management, online engagement/dissemination, and resources for decision-making and the media.
PRO4VIP received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 645584.
The eXtreme DataCloud (XDC) is a European Union Horizon 2020 funded project aimed at developing scalable technologies for federating storage resources and managing data in highly distributed computing environments. The services provided will be capable of operating at the unprecedented scale required by the most demanding, data intensive, research experiments in Europe and worldwide.
XDC will be based on existing tools, whose technical maturity is proved and that the project will enrich with new functionalities and plugins already available as prototypes (TRL6+) that will be brought at the production level (TRL8+) at the end of XDC.
The targeted platforms are the current and next generation e-Infrastructures deployed in Europe, such as the European Open Science Cloud (EOSC), the European Grid Infrastructure (EGI), the Worldwide LHC Computing Grid (WLCG) and the computing infrastructures funded by other public and academic initiatives.
All the developments will be community-driven and tested against real life use cases provided by the consortium partners representing research communities belonging to a variety of scientific domains: life science, astrophysics, high energy physics, photon science and clinical research.
eXtreme - DataCloud (XDC) has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 777367.